NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (122 reviews)

For research use only.

Catalog No.S2638

122 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Size Price Stock Quantity

10mM (1mL in DMSO) USD 141 In stock

5mg USD 88 In stock

10mg USD 151 In stock

50mg USD 466 In stock

200mg USD 1222 In stock

Bulk Size Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: +1-832-582-8158 [email protected]

Selleck's NU7441 (KU-57788) has been cited by 122 publications

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Targets

DNA-PK ^[1]
(Cell-free assay) mTOR ^[1]
(cell-free assay) PI3K ^[1]
(cell-free assay)

14 nM 1.7 μM 5 μM

In vitro
NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID

NCI-H1770 NV\3fpBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEKxOFMh|ryP MVLTRW5ITVJ?

A172 NYLQZoh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj0d|lKSzVyPUCuNVU{OTZizszN MlvwV2FPT0WU

NCI-H526 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG0TWM2OD1yLkK4OFA4KM7:TR?= MYXTRW5ITVJ?

HDLM-2 M13mWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\SdWlEPTB;MD6zNlM1PSEQvF2= M321[HNCVkeHUh?=

HuO-3N1 NFK0[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z4TGlEPTB;MD60OlY{PiEQvF2= NVnMPWJ3W0GQR1XS

NCI-SNU-1 NF[4UGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vRTmlEPTB;MD62NFk6PCEQvF2= MU\TRW5ITVJ?

SK-N-AS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDDTWM2OD1yLk[yNlE3KM7:TR?= MX7TRW5ITVJ?

LoVo M{fHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwOE[3OFkh|ryP NVfKZ5JKW0GQR1XS

LAMA-84 NVz6[nFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6zeYlzUUN3ME2wMlk5QDN|IN88US=> MXPTRW5ITVJ?

CTB-1 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW2WmV6UUN3ME2xMlEyPTR4IN88US=> M2m0S3NCVkeHUh?=

KP-N-YS NHPV[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHJN3NlUUN3ME2xMlE1OjNzIN88US=> NUjRZnY5W0GQR1XS

HH NH;i[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMUiwPVMh|ryP MnfJV2FPT0WU

CHL-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwMkGzOlgh|ryP NHP3eo1USU6JRWK=

NB7 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PiemlEPTB;MT6yOFc1PSEQvF2= NEDU[oRUSU6JRWK=

HL-60 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwM{ixPUDPxE1? MnPqV2FPT0WU

639-V MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD1zLkS0NVI5KM7:TR?= MkjGV2FPT0WU

NCI-H1793 NV;mXW82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHYc2xKSzVyPUGuOFU5PCEQvF2= MUXTRW5ITVJ?

NEC8 M361VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TOUGlEPTB;MT61OVM2KM7:TR?= NHH5T2pUSU6JRWK=

PA-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnmTWM2OD1zLkW4Nlk1KM7:TR?= MVfTRW5ITVJ?

D-423MG NYnreGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnrc4ZKSzVyPUGuOlk{PjFizszN M3\4SXNCVkeHUh?=

NCI-H292 M{X1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLQfJJKSzVyPUGuO|QxOTNizszN NXTydnhYW0GQR1XS

SK-MEL-1 NHLkU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTOTWM2OD1zLke5OFc6KM7:TR?= NWW3W3o6W0GQR1XS

LB2241-RCC M3fKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\nTGlEPTB;Mj6xOFE1PiEQvF2= NXzKXGtLW0GQR1XS

SK-MEL-3 NX6yVlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DwVWlEPTB;Mj6xOlQ6KM7:TR?= NVXQd4JzW0GQR1XS

MHH-PREB-1 NVz5SIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LsbWlEPTB;Mj6xOlYxQSEQvF2= MXvTRW5ITVJ?

BFTC-905 NH3IWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3TWM2OD1{LkG2Olg4KM7:TR?= NGqxO25USU6JRWK=

Ramos-2G6-4C10 NYTjZmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfLcpdKSzVyPUKuNVk6ODlizszN NIT3eYNUSU6JRWK=

G-361 M33VSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13UU2lEPTB;Mj6yNVY5KM7:TR?= NEH6UZpUSU6JRWK=

MOLT-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflUWFMUUN3ME2yMlIyQDh6IN88US=> MXXTRW5ITVJ?

DEL NFXXOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwM{W1OlQh|ryP Ml7KV2FPT0WU

MV-4-11 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H0VWlEPTB;Mj6zO|M6KM7:TR?= M2PCU3NCVkeHUh?=

SK-NEP-1 NHL1cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwM{i3PFMh|ryP M3WxW3NCVkeHUh?=

RS4-11 M4jJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJwNU[wNlMh|ryP MWDTRW5ITVJ?

HuH-7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDKd4xKSzVyPUKuOVY4ODJizszN MXTTRW5ITVJ?

A101D MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwNkGzN|gh|ryP MUjTRW5ITVJ?

KG-1 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\KOJRKSzVyPUKuOlc6OjRizszN NX76ZYJ[W0GQR1XS

KALS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XL[mlEPTB;Mj62PVY{OyEQvF2= NGTWOG1USU6JRWK=

VMRC-RCZ NYPndHVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PRUGlEPTB;Mj63O|MzQCEQvF2= NWLLXHlPW0GQR1XS

SK-UT-1 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XsfmlEPTB;Mz6xOVMyKM7:TR?= NHHJOIpUSU6JRWK=

SW962 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GydGlEPTB;Mz6yNFM2OiEQvF2= M4jVPHNCVkeHUh?=

DBTRG-05MG M4TnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwMkiwPFUh|ryP NGLYWXdUSU6JRWK=

PANC-08-13 NW\BTI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF61OVZKSzVyPUOuOFEzPzhizszN NH65OYVUSU6JRWK=

QIMR-WIL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m5eGlEPTB;Mz60NVM1OSEQvF2= MWrTRW5ITVJ?

SK-MEL-30 M134UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nIXmlEPTB;Mz60NlU6QCEQvF2= MYnTRW5ITVJ?

697 NXPTS|hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX2eZROUUN3ME2zMlQ1QTl|IN88US=> M3rPSnNCVkeHUh?=

NY MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7qUmdKSzVyPUOuOFUxOjJizszN NHHNRmFUSU6JRWK=

ES7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPtZmtKSzVyPUOuOFY4OjlizszN MlzmV2FPT0WU

JVM-3 M1Sxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwNEiwO|ch|ryP NHrzOGtUSU6JRWK=

U031 NXzuXotQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nRbGlEPTB;Mz61PVM3QCEQvF2= MVnTRW5ITVJ?

BHT-101 NGnsdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vNdGlEPTB;Mz61PVk5PSEQvF2= MmrGV2FPT0WU

8305C NIHJVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD1|Lk[xO|M3KM7:TR?= M1jYeXNCVkeHUh?=

MG-63 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;vTGVKSzVyPUOuOlI3PzZizszN M{jYfHNCVkeHUh?=

NOS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorITWM2OD1|Lk[1N|EzKM7:TR?= M1vGdHNCVkeHUh?=

YH-13 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNbnpHUUN3ME2zMlg4OTh7IN88US=> MmDrV2FPT0WU

LXF-289 M1jwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGVplKSzVyPUOuPVExPDFizszN MlrlV2FPT0WU

GOTO NEfMUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHLZVVKSzVyPUOuPVE1QSEQvF2= MkPKV2FPT0WU

EKVX MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPyTWM2OD12LkKyOVI1KM7:TR?= NUfCfZQyW0GQR1XS

CAL-51 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrYOItKSzVyPUSuNlQ5PTRizszN NHHzOopUSU6JRWK=

AN3-CA NWnIUW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37COmlEPTB;ND6yOVgyOyEQvF2= MlPYV2FPT0WU

IA-LM MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT4OGRuUUN3ME20MlI4QTN3IN88US=> NYXuWmdGW0GQR1XS

KU-19-19 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrtVZVQUUN3ME20MlMzQTJzIN88US=> M1nVeHNCVkeHUh?=

A704 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi0eG9TUUN3ME20MlQxQDh6IN88US=> MVzTRW5ITVJ?

RH-18 NFHEdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnodpBKSzVyPUSuOFQ6PTNizszN MnKwV2FPT0WU

IST-MEL1 M4n1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jCZmlEPTB;ND61PFI3OyEQvF2= MkOxV2FPT0WU

LU-134-A M4PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwNUm2PFUh|ryP MXTTRW5ITVJ?

SF126 NH7uTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf2VZlyUUN3ME20MlYxPzF3IN88US=> MUPTRW5ITVJ?

EFO-27 NVH3SWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRwNk[1NlUh|ryP NFnTc3FUSU6JRWK=

SN12C M2Tod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7sTWM2OD12LkexPFk5KM7:TR?= NGK2S2ZUSU6JRWK=

L-363 NFLLe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwN{exNVYh|ryP MnLHV2FPT0WU

MEL-HO NWn4foZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTHeoJKSzVyPUSuO|c6QDlizszN NY\1VpNTW0GQR1XS

TYK-nu M4\NTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwOECxNlgh|ryP NHn4b3lUSU6JRWK=

MDA-MB-415 NHT3No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjmenZKSzVyPUWuNFA{OTRizszN MWXTRW5ITVJ?

HCC70 M1\PVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0N3oxUUN3ME21MlA{QTN7IN88US=> M4iz[XNCVkeHUh?=

IGROV-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLvPIRKSzVyPUWuNlUzQTJizszN NWfi[IsyW0GQR1XS

NCI-H1355 M4DiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXLN5ZqUUN3ME21MlI6PiEQvF2= MmLsV2FPT0WU

23132-87 NG\XSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3kTWM2OD13LkOyNFI1KM7:TR?= M3TETnNCVkeHUh?=

NB69 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLPdG5IUUN3ME21MlMzPDJizszN NVm0eXBZW0GQR1XS

HSC-2 NE\G[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;TcoZKSzVyPUWuOFE4PzNizszN NXvpSIZOW0GQR1XS

KYSE-410 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n1dmlEPTB;NT60O|Y{PiEQvF2= MWXTRW5ITVJ?

GCIY NGD0cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tW3dDUUN3ME21MlUyOzd6IN88US=> MWrTRW5ITVJ?

A427 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrsOXVKSzVyPUWuOVM3PjFizszN M17STXNCVkeHUh?=

ChaGo-K-1 M1z2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HEPGlEPTB;NT61OlU6QSEQvF2= NHzBfFhUSU6JRWK=

PFSK-1 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Me2JKSzVyPUWuOlIyQTRizszN NHTydW9USU6JRWK=

MLMA M3fLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SyOmlEPTB;NT64N|YxPiEQvF2= NWTPUIxbW0GQR1XS

RVH-421 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zWNGlEPTB;Nj6wO|M{QCEQvF2= NE\Vc41USU6JRWK=

LB1047-RCC MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHIe4pmUUN3ME22MlE4PTJ{IN88US=> MlvXV2FPT0WU

MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle5TWM2OD14LkOyO|IyKM7:TR?= MnvnV2FPT0WU

J-RT3-T3-5 M1jucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PxZ2lEPTB;Nj62N|I6OSEQvF2= NWTN[XUyW0GQR1XS

UM-UC-3 M{[0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDzUFB{UUN3ME22MlY1OzN2IN88US=> MYnTRW5ITVJ?

IST-SL1 NEnMdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXDTWM2OD14Lk[5N|Y6KM7:TR?= MoTUV2FPT0WU

NB14 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZwN{m3OlEh|ryP NYKwTZhkW0GQR1XS

NBsusSR M1LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTTNmhFUUN3ME22MlgzPTB{IN88US=> MXzTRW5ITVJ?

D-263MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\zd2lEPTB;Nj65NVA3QCEQvF2= MofGV2FPT0WU

NCI-H2347 M3zrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD14LkmzNlE{KM7:TR?= NXHSR4tSW0GQR1XS

ES8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv2N5hXUUN3ME22Mlk4PTh6IN88US=> MULTRW5ITVJ?

786-0 NV\s[lhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTdwMEm3PFYh|ryP NWrPcW11W0GQR1XS

EPLC-272H MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTdwMU[yOFYh|ryP MnH2V2FPT0WU

CAPAN-1 M4fZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CzSWlEPTB;Nz6yOFM2QSEQvF2= MUXTRW5ITVJ?

NCI-H82 NGjxcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\YXmlEPTB;Nz6yOlY2QSEQvF2= NFnqc5NUSU6JRWK=

G-402 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfldJBKSzVyPUeuN|AxPTFizszN MX\TRW5ITVJ?

SW982 NHrSRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj3TWM2OD15LkOwNlA{KM7:TR?= NHK5c49USU6JRWK=

OVCAR-4 NXnpd41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPzOWxKSzVyPUeuN|E{OjhizszN M3[1WnNCVkeHUh?=

KARPAS-299 NEDEW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnWTWM2OD15LkOyOlIzKM7:TR?= Mmf1V2FPT0WU

MIA-PaCa-2 NWezS3g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn5TWM2OD15LkO2PFI{KM7:TR?= NF\4Xm5USU6JRWK=

AU565 NHPHPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXuNGFKSzVyPUeuOVk5OzNizszN NFnKUY9USU6JRWK=

GAMG MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwNkSxN|Eh|ryP NEjzcVRUSU6JRWK=

HuO9 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFntclNKSzVyPUeuO|E4PDNizszN MYnTRW5ITVJ?

ACN NVfvUZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfh[lhGUUN3ME23Mlc1OzNizszN MWPTRW5ITVJ?

RO82-W-1 NHnqRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdwN{S1N|Mh|ryP NYnNW49SW0GQR1XS

NKM-1 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwN{S5OVUh|ryP M3XRPXNCVkeHUh?=

CAL-12T NYP1ZWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXVmlEPTB;Nz65OFM2OiEQvF2= MnjMV2FPT0WU

FADU NGe1SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hwb2lEPTB;OD6wN|Y2PCEQvF2= M4rJbnNCVkeHUh?=

NCI-H28 NF3zXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITFS2xKSzVyPUiuNVY6PjJizszN M1\tOHNCVkeHUh?=

LCLC-97TM1 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRThwMkGxNlIh|ryP M{LkN3NCVkeHUh?=

CHP-134 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M323OGlEPTB;OD6yOFE5PSEQvF2= MXHTRW5ITVJ?

HT-1080 M3TqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwOGxKSzVyPUiuNlUxQTNizszN M{XTW3NCVkeHUh?=

PC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRThwMkezPVIh|ryP NH3N[HlUSU6JRWK=

SNU-449 NYnDZphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PaemlEPTB;OD6yO|k{KM7:TR?= M{XhV3NCVkeHUh?=

VA-ES-BJ NX;aR|RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGwWmJKSzVyPUiuN|Q3QDZizszN MX\TRW5ITVJ?

HT NG\6NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnxdYRwUUN3ME24MlM3PDlizszN NFnwNVlUSU6JRWK=

HOS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnhTZBKSzVyPUiuN|c2QDlizszN MVnTRW5ITVJ?

KNS-62 NFvzeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETGfnhKSzVyPUiuN|c4PjJizszN M{PYNHNCVkeHUh?=

OAW-42 NVfHSWtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRThwOUW5OlQh|ryP MYfTRW5ITVJ?

A549 NHOwfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTlwMEm2NVIh|ryP MWDTRW5ITVJ?

CAKI-1 M{fHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTlwMU[2NUDPxE1? NUDUSJJrW0GQR1XS

HCC1937 M4PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DYemlEPTB;OT62PVg3PSEQvF2= NF\KZZNUSU6JRWK=

GI-ME-N Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfsTWM2OD17LkewNVM4KM7:TR?= MoLjV2FPT0WU

DU-4475 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTlwOU[5N|kh|ryP NI\BWpFUSU6JRWK=

EM-2 NXftRmoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFyLkK0NlYh|ryP MmjXV2FPT0WU

NCI-H1755 NYjtd4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3MTWM2OD1zMD6yOFI5KM7:TR?= M2HPe3NCVkeHUh?=

NCI-H1437 M4jqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HEOGlEPTB;MUCuOVczPSEQvF2= NXHxOnV1W0GQR1XS

VM-CUB-1 NUHPU3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H5N2lEPTB;MUCuOlE3PCEQvF2= MYLTRW5ITVJ?

A2058 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjy[GJKSzVyPUGwMlY1ODRizszN MkjaV2FPT0WU

BPH-1 NIqxNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFyLkexOFUh|ryP NYTxV2RnW0GQR1XS

NB5 M{LmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXOUnBKSzVyPUGwMlc2PTlizszN M3PCbnNCVkeHUh?=

G-401 NVnUcVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWcJNtUUN3ME2xNE44PjJ4IN88US=> MkmzV2FPT0WU

CAL-72 M2XET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXKeHVjUUN3ME2xNE45ODl2IN88US=> MV3TRW5ITVJ?

SK-MEL-28 NGnvNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPnSpV{UUN3ME2xNE45OjB{IN88US=> NWj2OYlUW0GQR1XS

C32 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PjSWlEPTB;MUCuPFM1PyEQvF2= NFfEUJFUSU6JRWK=

NCI-H1155 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjEUnJvUUN3ME2xNE45Ozd4IN88US=> M1G0NXNCVkeHUh?=

BB49-HNC MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X2OmlEPTB;MUCuPFU5PiEQvF2= M2XXcXNCVkeHUh?=

GMS-10 NGPhfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFyLki5O|Eh|ryP M{DJOXNCVkeHUh?=

K5 M1;ZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zKNGlEPTB;MUCuPVA4OSEQvF2= M33DUXNCVkeHUh?=

OS-RC-2 NEfadJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFzLkC1OVkh|ryP MljsV2FPT0WU

HTC-C3 NFzkOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vE[WlEPTB;MUGuNFcyPCEQvF2= MUTTRW5ITVJ?

LB996-RCC M4jWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTOFhCUUN3ME2xNU4xPzJ|IN88US=> MkPwV2FPT0WU

NCI-H1563 M3TwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDIOWhKSzVyPUGxMlExOTFizszN NW\YcHh5W0GQR1XS

CAL-54 M4XZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLkS4NVEh|ryP M4jTdnNCVkeHUh?=

WM-115 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF33OYtKSzVyPUGxMlY5OjRizszN MVrTRW5ITVJ?

COLO-684 NIDGd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrnTWM2OD1zMT63NlY4KM7:TR?= MVfTRW5ITVJ?

HOP-62 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLhPWRbUUN3ME2xNU44PTB6IN88US=> Ml\5V2FPT0WU

NCI-H650 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFzLki5OlEh|ryP Ml7uV2FPT0WU

TE-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjSeIFiUUN3ME2xNU46OzF3IN88US=> M{Oxc3NCVkeHUh?=

COLO-679 NHzvR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6z[YhwUUN3ME2xNU46PDZizszN MoXBV2FPT0WU

FTC-133 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETudldKSzVyPUGyMlAxPzZizszN NWTKS5dtW0GQR1XS

D-283MED MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGizNoNKSzVyPUGyMlA2PjlizszN NVexXmRYW0GQR1XS

SK-PN-DW NYHSRmpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW4W|Z3UUN3ME2xNk4yQTB{IN88US=> MWjTRW5ITVJ?

BALL-1 M3HaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXQOlVKSzVyPUGyMlI3PjJizszN NGnVb4ZUSU6JRWK=

GT3TKB M4\TTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF{LkOwO|Qh|ryP NGWyWXVUSU6JRWK=

HOP-92 NVHNWFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnoTlk4UUN3ME2xNk42OjN|IN88US=> MV\TRW5ITVJ?

M14 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTMTWM2OD1zMz6wN|M2KM7:TR?= NILIbmlUSU6JRWK=

SKG-IIIa Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfoR21bUUN3ME2xN{4xPTV2IN88US=> M1fCSXNCVkeHUh?=

Becker MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\6OnRvUUN3ME2xN{4xPThizszN NFXOeIZUSU6JRWK=

ES5 M{\VXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkU21KSzVyPUGzMlE{PTZizszN M3nCbHNCVkeHUh?=

NCI-H2030 NXriS5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIOGRKSzVyPUGzMlIxPjJizszN MV\TRW5ITVJ?

SNU-423 NVHCdohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXjTWM2OD1zMz6zPFEh|ryP NY\SV4NuW0GQR1XS

CP50-MEL-B MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvFTWM2OD1zMz62NlMzKM7:TR?= NFX3THhUSU6JRWK=

NCI-H1092 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF|Lke0O|Uh|ryP MmHRV2FPT0WU

8-MG-BA NE\Lc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF|Lke1NVMh|ryP MX;TRW5ITVJ?

CAL-27 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF2LkC3Nlch|ryP NF7uSWZUSU6JRWK=

AGS Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fOVmlEPTB;MUSuNVMyQSEQvF2= MWjTRW5ITVJ?

MZ2-MEL NYfKUYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PTcWlEPTB;MUSuNVQ5QCEQvF2= NVPYSndkW0GQR1XS

BFTC-909 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fTbWlEPTB;MUSuOVA2PSEQvF2= M2CxS3NCVkeHUh?=

D-566MG MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQR|lKSzVyPUG0Mlc4ODZizszN MX\TRW5ITVJ?

MZ7-mel MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG2PHV{UUN3ME2xOU4yODZ5IN88US=> M1\jdHNCVkeHUh?=

TE-5 M4LXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF3LkKzN|Mh|ryP MXzTRW5ITVJ?

647-V MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7CSlFMUUN3ME2xOU4zPzB3IN88US=> MnuzV2FPT0WU

DMS-114 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknkTWM2OD1zNT6zNlkyKM7:TR?= Mm\sV2FPT0WU

ME-180 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHX[4xoUUN3ME2xOU41Pzh|IN88US=> M371OXNCVkeHUh?=

MS-1 NFryfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOye5VKSzVyPUG1MlU3OjNizszN MUHTRW5ITVJ?

NUGC-3 NXj0e29PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYruTZJZUUN3ME2xOU43OjR3IN88US=> MojXV2FPT0WU

GB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTIU4JQUUN3ME2xOU43PDN5IN88US=> MXjTRW5ITVJ?

LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF3Lki5NVkh|ryP NV\I[ZV5W0GQR1XS

NCI-H1304 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\3WWk5UUN3ME2xOU45QTJ6IN88US=> MXrTRW5ITVJ?

KURAMOCHI NIHDfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF3Lkm3NUDPxE1? MnLLV2FPT0WU

SW1783 NV3aOod3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF4LkC5PVMh|ryP NV3IOplrW0GQR1XS

EGI-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF4LkWzOlUh|ryP NVLYelg{W0GQR1XS

KGN NIHwTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF4LkW1PFYh|ryP MlX2V2FPT0WU

PANC-03-27 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLObIJqUUN3ME2xOk44PjZ{IN88US=> MX;TRW5ITVJ?

RH-1 NYr4SYVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjsTWM2OD1zNj64NlUh|ryP NYriWFJJW0GQR1XS

HT-1376 NVHKZod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF4Lki0OFYh|ryP M1zaXnNCVkeHUh?=

ZR-75-30 NGHEPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1zNj65N|YyKM7:TR?= MX\TRW5ITVJ?

TI-73 NVWxbGpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF4Lkm0NFgh|ryP MkPoV2FPT0WU

TK10 NVLXSmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DnWmlEPTB;MUeuNFA4QSEQvF2= MVnTRW5ITVJ?

SW684 NGj3VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13GXWlEPTB;MUeuNFE2PCEQvF2= M3zE[XNCVkeHUh?=

RPMI-8866 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6fGlEPTB;MUeuNFY6QSEQvF2= NVjPTmY4W0GQR1XS

LNCaP-Clone-FGC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfsZYtKSzVyPUG3MlUzODFizszN M2CwbHNCVkeHUh?=

NCI-H2291 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF6LkSzOFUh|ryP NVLEWGNIW0GQR1XS

T47D NHy2eWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnBO2VKSzVyPUG4MlQ5QCEQvF2= MYnTRW5ITVJ?

A204 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml35TWM2OD1zOD61OFUzKM7:TR?= MoXJV2FPT0WU

HT-144 NIi1dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfYR|dKSzVyPUG4Mlc1OjdizszN NH3mXIxUSU6JRWK=

MDA-MB-361 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF7LkC3NVQh|ryP NWnHcmduW0GQR1XS

HCC1806 NF\oU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ST2lEPTB;MUmuNVU6OSEQvF2= NFq1c5hUSU6JRWK=

NCI-H596 NGTzOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorPTWM2OD1zOT62N|kyKM7:TR?= NFq4fm1USU6JRWK=

K-562 NELrW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtTWM2OD1zOT64PVI3KM7:TR?= NI\MW3pUSU6JRWK=

D-336MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ZTWM2OD1zOT65N|IzKM7:TR?= M1XEfXNCVkeHUh?=

SK-MEL-2 NFXMVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHU[IxKSzVyPUKwMlE2PTlizszN Mk\QV2FPT0WU

HEC-1 M1\KNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTxTWM2OD1{MD60PVc5KM7:TR?= MnvpV2FPT0WU

EW-13 NHLXWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvVSlM5UUN3ME2yNE42PDR|IN88US=> NXnvXVkxW0GQR1XS

Hs-578-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TodmlEPTB;MkCuOVU5OyEQvF2= NWnzeYxiW0GQR1XS

SJSA-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj6dZFHUUN3ME2yNE42Pjh6IN88US=> NEfDOoxUSU6JRWK=

RCC10RGB MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UbWFKSzVyPUKwMlY4OTlizszN NEXxfXZUSU6JRWK=

LAN-6 NH;HVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTxTVhiUUN3ME2yNU4xOzl4IN88US=> M4TTRXNCVkeHUh?=

NCI-H1048 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJzLkKyOVgh|ryP NULaZldQW0GQR1XS

CW-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS0SYlvUUN3ME2yNU4zPzB3IN88US=> NYTuRYx5W0GQR1XS

HCC2157 M13ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnEVpBKSzVyPUKxMlM3KM7:TR?= MX7TRW5ITVJ?

EW-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjvNG5KSzVyPUKxMlM4PiEQvF2= M2DsZ3NCVkeHUh?=

A253 NEPNfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHThfIRKSzVyPUKxMlQ1QDFizszN NY[2NGtlW0GQR1XS

BE-13 NFjpcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP2b4RKSzVyPUKxMlYyOTNizszN NVXUTZROW0GQR1XS

KINGS-1 NGXW[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJdplwUUN3ME2yNU43OzF4IN88US=> MWPTRW5ITVJ?

ETK-1 NWPOWFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzIcVM4UUN3ME2yNU45OTV{IN88US=> MXzTRW5ITVJ?

NCI-H2452 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rFcmlEPTB;MkGuPFY1PyEQvF2= M1v5W3NCVkeHUh?=

HPAF-II MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJzLki5NlMh|ryP NIDJfm9USU6JRWK=

D-542MG M4nSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLrNphKSzVyPUKxMlkxPjlizszN MX3TRW5ITVJ?

NCI-H630 M{\mVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ{LkCyPVYh|ryP MUXTRW5ITVJ?

TGBC11TKB MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLYeWY4UUN3ME2yNk4xPDlizszN MVLTRW5ITVJ?

BCPAP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLJO|NKSzVyPUKyMlYyOSEQvF2= MoLtV2FPT0WU

HLE M3PiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ{Lk[5O{DPxE1? M1HNXnNCVkeHUh?=

NCI-H727 NF75So9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnsdW5KSzVyPUKyMlc{PSEQvF2= NX\3epB1W0GQR1XS

RD MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG1VVZbUUN3ME2yNk44PTF6IN88US=> NVnwXINCW0GQR1XS

NCI-H522 NFrVPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG0RYpKSzVyPUKyMlg1OzFizszN Mkj4V2FPT0WU

CGTH-W-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LqTmlEPTB;MkOuNFY1OSEQvF2= NFXte5FUSU6JRWK=

SK-LU-1 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjHfGJKSzVyPUKzMlQ3QDNizszN NV24To5ZW0GQR1XS

BB65-RCC NY\2[llnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lh[2lEPTB;MkOuO|g3OyEQvF2= NYnm[3RyW0GQR1XS

HSC-3 NFL6eVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;oTWM2OD1{Mz64OVI4KM7:TR?= M{\vZnNCVkeHUh?=

SK-MES-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDqb|ZxUUN3ME2yOE4xOTZzIN88US=> NHfuNHJUSU6JRWK=

DB M{LMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDvTWM2OD1{ND6xNFI5KM7:TR?= Ml7UV2FPT0WU

HO-1-N-1 NWPGVYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17IcmlEPTB;MkSuN|A6OyEQvF2= MoX1V2FPT0WU

MKN1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ2Lk[4JO69VQ>? NGXlcYJUSU6JRWK=

MN-60 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wTWM2OD1{ND64OVE6KM7:TR?= NIHZe5NUSU6JRWK=

8505C M1:3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrvSmNuUUN3ME2yOU4yQDR3IN88US=> MX7TRW5ITVJ?

COLO-320-HSR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ3LkKyNFgh|ryP M4nkPHNCVkeHUh?=

BB30-HNC NHnLPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOw[XhKSzVyPUK1MlI1QDNizszN NWjIT|dQW0GQR1XS

KM12 M{jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ3LkW4NFch|ryP MUTTRW5ITVJ?

NB13 M1;MZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPETWM2OD1{NT61PFk5KM7:TR?= MlLyV2FPT0WU

HCC2998 NEfIR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PUemlEPTB;Mk[uNFI5OyEQvF2= M4fHenNCVkeHUh?=

U-118-MG Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtTWM2OD1{Nj6wPFA5KM7:TR?= MVvTRW5ITVJ?

NB10 MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH1TWM2OD1{Nj6yN|Qh|ryP MXXTRW5ITVJ?

SK-LMS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD1{Nz6wO|A1KM7:TR?= M4\SSHNCVkeHUh?=

SW1573 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jWPWlEPTB;MkeuNVEh|ryP NVSzNVl1W0GQR1XS

LB373-MEL-D NVPTbJJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjLTIw6UUN3ME2yO{4yOjl2IN88US=> M{TPV3NCVkeHUh?=

DK-MG NUfic|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj3cpFKSzVyPUK3MlE5OTdizszN M4e1cHNCVkeHUh?=

RMG-I NHPpPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL5W4VqUUN3ME2yO{4zODJ7IN88US=> MkHSV2FPT0WU

SW1088 M1vKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ5LkWwOFIh|ryP NV3wUHdIW0GQR1XS

SK-OV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorUTWM2OD1{Nz63OVk{KM7:TR?= M3vJTXNCVkeHUh?=

KP-N-YN NEXndohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaTWM2OD1{Nz64NFQ{KM7:TR?= NHfKe2dUSU6JRWK=

RPMI-7951 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrLW5E1UUN3ME2yPE4zPDV4IN88US=> NUD5dZVCW0GQR1XS

CaR-1 NWrqT4QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn30TWM2OD1{OD61OVgzKM7:TR?= NE\qfIdUSU6JRWK=

MKN7 M1HkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ6LkW5OlQh|ryP M2XYVnNCVkeHUh?=

CHP-212 M1y4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ6Lke0NFEh|ryP NXjaWYF7W0GQR1XS

KYSE-450 NYnRT3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PSeGlEPTB;MkiuPFA6OSEQvF2= NGSzRmRUSU6JRWK=

RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPZOYNCUUN3ME2yPU4zQTB4IN88US=> M{\UVnNCVkeHUh?=

P30-OHK MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXCNJFKSzVyPUK5MlMxPDhizszN MkXOV2FPT0WU

Ca9-22 M2H1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ7LkSyPVkh|ryP NFS2WJFUSU6JRWK=

RT-112 NW\RRYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G5d2lEPTB;MkmuOFYyOSEQvF2= NYXJdVhWW0GQR1XS

ES1 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zbGZKSzVyPUK5Mlg2PDRizszN MYnTRW5ITVJ?

HCE-4 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHZTWM2OD1{OT64O|g3KM7:TR?= NHXEfWpUSU6JRWK=

AM-38 M{KxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\VOVVKSzVyPUOwMlA3ODZizszN Mn;0V2FPT0WU

AsPC-1 NFO3TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL5TWM2OD1|MD64NFU{KM7:TR?= NYX3cod4W0GQR1XS

TE-9 M4D3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Tyb2lEPTB;M{CuPFc{PyEQvF2= NU\EXZBRW0GQR1XS

HuP-T4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNyLkm2N|gh|ryP NGLObFdUSU6JRWK=

LB2518-MEL MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaTWM2OD1|MT6wO|Q1KM7:TR?= NEHrNVFUSU6JRWK=

NCI-H1703 NHXnTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrRfnpUUUN3ME2zNU4xQTB3IN88US=> NWLiXlVDW0GQR1XS

NCI-H2228 NH\xZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHThNJJKSzVyPUOxMlQ3PTFizszN NYLUXlhYW0GQR1XS

SCC-4 NXHofY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNzLkmxPFEh|ryP MVfTRW5ITVJ?

KNS-81-FD NG\S[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN{LkCxNlgh|ryP Mn7BV2FPT0WU

NTERA-S-cl-D1 M4rVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILkOo5KSzVyPUOyMlA4OzlizszN MkjlV2FPT0WU

Daoy M3zPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PabWlEPTB;M{KuNFg{QCEQvF2= MkPEV2FPT0WU

ES4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LLVGlEPTB;M{KuN|kzOiEQvF2= NGj4WYtUSU6JRWK=

MHH-ES-1 NYSx[483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDMWGFFUUN3ME2zNk41QDd{IN88US=> NEnwO5RUSU6JRWK=

C-33-A NH\hfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjKTWM2OD1|Mj63O|I5KM7:TR?= NV\CZ5NDW0GQR1XS

BHY MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\GPWFKSzVyPUOyMlk1QTVizszN MoTjV2FPT0WU

Detroit562 NWfaSoFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN|Lk[2OVch|ryP NIDXboZUSU6JRWK=

EW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHGZYJKSzVyPUOzMlk{OjJizszN MnPPV2FPT0WU

NCI-H1395 NXu4fGlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPuTWM2OD1|ND6wO|k6KM7:TR?= M{\LU3NCVkeHUh?=

KM-H2 NVy1cWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN4LkS3OFMh|ryP MUHTRW5ITVJ?

NCI-H520 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX6b5RKSzVyPUO2Mlc2PDFizszN M{LnUXNCVkeHUh?=

D-392MG M{DXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN5LkOzOFQh|ryP NEGxRWtUSU6JRWK=

NOMO-1 NGXDTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLjR4NKSzVyPUO3MlgxQDlizszN NX7XeGtGW0GQR1XS

TE-6 NWPteFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rwPGlEPTB;M{iuNVI1KM7:TR?= NVXvdZFHW0GQR1XS

HT-3 NEL5fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN6LkS0N|Yh|ryP NXfrU4ZPW0GQR1XS

RPMI-8226 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN6Lkm1NVkh|ryP NVnH[ppHW0GQR1XS

U251 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN7LkCxNlQh|ryP NXvaUodSW0GQR1XS

GCT NYS1dlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN7LkG4OVIh|ryP NXPYZVh{W0GQR1XS

A431 M1fNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHZTWM2OD1|OT6xPFk1KM7:TR?= M3n0OHNCVkeHUh?=

TE-12 NXTRTYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfZO2w1UUN3ME2zPU4zPDR6IN88US=> MoLsV2FPT0WU

HMV-II M2DzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDVTWM2OD1|OT61NFQ4KM7:TR?= M4jEcnNCVkeHUh?=

IST-MES1 M2XuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTrPIo2UUN3ME20NE4yPTB{IN88US=> NX7ndVRTW0GQR1XS

SW13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwdVdKUUN3ME20NE42OTlizszN M1nuXnNCVkeHUh?=

SF295 M4PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPOPJFKSzVyPUSwMlgxPjZizszN NYC2b2x[W0GQR1XS

MDA-MB-157 M1HldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTDOGxKUUN3ME20NE46PDZ{IN88US=> MWfTRW5ITVJ?

TE-1 NIP2W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zqcmlEPTB;NEGuPFcyPCEQvF2= NFW3RlhUSU6JRWK=

HuCCT1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v2WmlEPTB;NEKuOVI5QSEQvF2= NUj4OIVZW0GQR1XS

KYSE-510 NWnSfGw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrQTWM2OD12Mz6xO|U1KM7:TR?= M4ezXHNCVkeHUh?=

NCI-H358 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\FVnhKSzVyPUS0MlA{ODRizszN M4LUUnNCVkeHUh?=

SW900 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG3SIJXUUN3ME20OE4xPzV6IN88US=> NHry[HRUSU6JRWK=

CAS-1 M3i4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nITGlEPTB;NESuNFk6OSEQvF2= MlzuV2FPT0WU

TE-8 M3jOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;zWm9KSzVyPUS0MlU3PThizszN NEHvdZZUSU6JRWK=

P12-ICHIKAWA NH;MR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPqTWM2OD12ND62NVEzKM7:TR?= Mn7GV2FPT0WU

YKG-1 NU\0WI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLNTWM2OD12ND63PFEh|ryP MXPTRW5ITVJ?

SNU-C2B NIXRVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTR2Lke5NFMh|ryP M3zGUHNCVkeHUh?=

LCLC-103H NWn6fYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj5UWpHUUN3ME20OE45PzB|IN88US=> MkDGV2FPT0WU

U-87-MG NWnkWGo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\zS2lEPTB;NEWuNVAzOiEQvF2= Mk[xV2FPT0WU

HAL-01 NH;5cXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3bmlEPTB;NEWuNVM4QSEQvF2= M13GfXNCVkeHUh?=

OVCAR-8 NW\we|FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXIbXZKSzVyPUS1MlM2PjRizszN Mn3BV2FPT0WU

KYSE-150 M3rMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPTNYhKSzVyPUS3MlExPTJizszN M13adHNCVkeHUh?=

OE33 M4j3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImzfFVKSzVyPUS3MlE1OjlizszN MkPEV2FPT0WU

CAL-62 NEeyR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnE[ldKSzVyPUS3MlQxPjhizszN MlHrV2FPT0WU

TCCSUP NVrMdIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjQc3lKSzVyPUS3MlYzPjRizszN M2jpdXNCVkeHUh?=

H4 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ocYN1UUN3ME20O{43PjJzIN88US=> MorTV2FPT0WU

CP66-MEL MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzseplKSzVyPUS4MlA4ODRizszN MUHTRW5ITVJ?

SNB75 M3vOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhT3U5UUN3ME20PE4yQDd2IN88US=> NH3Tc3lUSU6JRWK=

Mo-T M4fNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LVTWlEPTB;NEiuNlc6KM7:TR?= MVTTRW5ITVJ?

BT-549 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;k[2VtUUN3ME20PE4{PzJ7IN88US=> MkPOV2FPT0WU

IGR-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPVT|NEUUN3ME20PE43PjR3IN88US=> NWDkWpVOW0GQR1XS

NCI-H1299 NUfPTVEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3TRWNKSzVyPUS4MlczPDhizszN MVfTRW5ITVJ?

ALL-PO MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR7LkmyOlgh|ryP MXvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods Test Index PMID

Western blot
p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51;

PubMed: 29344644      Oncol Rep

SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR.

p-mTOR(Ser2448) / mTOR / p-S6K(Thr389);

PubMed: 25714019      Oncotarget

Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.

29344644 25714019

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:
^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells

Concentrations: 0.5 μM or 1 μM

Incubation Time: 17 hours

Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:
^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts

Dosages: 10 mg/kg

Administration: Intraperitoneally administrated
(Only for Reference)

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

[3] Tavecchio M, et al. Cancer Chemother Pharmacol, 2012, 69(1), 155-164.

[4] Cruet-Hennequart S, et al. DNA Repair (Amst), 2006, 5(4), 491-504.

[5] Willmore E, et al. Clin Cancer Res, 2008, 14(12), 3984-3992.

[6] Elliott SL, et al. Br J Haematol, 2011, 152(1), 61-71.

[7] Robert F, et al. Genome Med. 2015, 7:93.

- Collapse

Solubility (25°C)

In vitro DMSO 4 mg/mL warmed (9.67 mM)

Water Insoluble

Ethanol Insoluble

In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight 413.49

Formula
C₂₅H₁₉NO₃S

CAS No. 503468-95-9

Storage 3 years-20°C powder
2 years-80°C in solvent

Synonyms N/A

Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O %DMSO+ %

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Method for preparing in vivo formulation：Take μL DMSO master liquid,next add μL Corn oil，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
           2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

=

×

×

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

C1

V1

C2

V2

×

=

×

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions

Concertration (start):

Dilution-folds:

Computed Result

C1=C0/X C1: LOG(C1):

C2=C1/X C2: LOG(C2):

C3=C2/X C3: LOG(C3):

C4=C3/X C4: LOG(C4):

C5=C4/X C5: LOG(C5):

C6=C5/X C6: LOG(C6):

C7=C6/X C7: LOG(C7):

C8=C7/X C8: LOG(C8):

Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

= × ×

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name:

* E-Mail:

Phone:

* Comments:

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?

Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.

Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?

Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.

Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.

Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

NU7026

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.

KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Selleck's NU7441 (KU-57788) has been cited by 122 publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

In vivo Formulation Calculator (Clear solution)

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)

Selleck's NU7441 (KU-57788) has been cited by 122 publications

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download NU7441 (KU-57788) SDF

In vivo Formulation Calculator (Clear solution)

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Related DNA-PK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)